Skip to contentG
GeneDx Holdings Corp.
G
WGSGeneDx Holdings Corp. Q2 2023 · 10-Q
Revenue$48.71M$48.71M+34.7% vs Q2 2022 Net Income-$46.72M-$46.72MN/M vs Q2 2022 EPS Diluted-$1.84-$1.84N/M vs Q2 2022 Gross Profit$18,757,000N/M Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GeneDx Holdings Corp. · CIK 1818331 · Engraved from SEC EDGAR
Operating Cash Flowderived-$53,501,000N/M Free Cash Flowderived-$56,263,000N/M Margins · derivedGross margin38.5%+120.3 pt vs Q2 2022
Operating margin-106.0%+343.7 pt vs Q2 2022
Net margin-95.9%+141.1 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 8, 2023 · 39 d after period end